Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebentafusp in unresectable or metastatic clear cell sarcoma
ISRCTN24846895Phase 2Recruiting
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Start
- Jan 2026
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of tebentafusp in clear cell sarcoma (CCS) (2 arms), sponsored by Sarcoma Alliance for Research through Collaboration. Primary endpoint: Disease progression at 24 weeks. Started Jan 2026; status: recruiting.
02
Drugs
tebentafusp
03
Conditions
clear cell sarcoma (CCS)
Beyond the preview
Go deeper on ISRCTN24846895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN24846895.